Pharmacokinetics of voriconazole during continuous venovenous haemodiafiltration

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 5, 2007, Pages 1085-1090

  Fuhrmann, Valentin ^a   Schenk, Peter ^a   Jaeger, Walter ^b   Miksits, Michaela ^b   Kneidinger, Nikolaus ^a   Warszawska, Joanna ^a   Holzinger, Ulrike ^a   Kitzberger, Reinhard ^a   Thalhammer, Florian ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antimycotic agents; Intensive care unit; Pharmacokinetics; Renal replacement therapy

Indexed keywords

CATECHOLAMINE; FENTANYL; HEPARIN; PROPOFOL; VORICONAZOLE;

ACUTE KIDNEY FAILURE; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTINUOUS HEMODIAFILTRATION; CRITICALLY ILL PATIENT; DOSE LIVER FUNCTION RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER CIRRHOSIS; MALE; MYCOSIS; TREATMENT DURATION;

ADULT; AGED; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CRITICAL ILLNESS; FEMALE; HALF-LIFE; HEMODIAFILTRATION; HUMANS; KIDNEY FAILURE, ACUTE; MALE; MIDDLE AGED; MYCOSES; PYRIMIDINES; TRIAZOLES;

EID: 35448955384     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm349     Document Type: Article

References (33)

1. Herbrecht R. Voriconazole: Therapeutic review of a new azole antifungal. Expert Rev Anti-infect Ther 2004; 2: 485-97.
2. Johnson LB, Kauffmann CA. Voriconazole: A new triazole anti-fungal agent. Clin Infect Dis 2003; 36: 630-7.
3. Walsh TJ, Pappas P, Winston DJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346 225-34.
4. Kullberg BJ, Sobel JD, Ruhnke M et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidemia in non neutropenic patients: A randomised non-inferiority trial. Lancet 2005; 366: 1435-42.
5. Ally R, Schurmann D, Kreisell W et al. A randomized double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001; 33: 1447-54.
6. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
7. Boucher HW, Groll AH, Chiou CC et al. Newer systemic antifungal agents. Pharmacokinetics, safety and efficacy. Drugs 2004; 64 1997-2020.
8. Ostrosky-Zeichner L. Prophylaxis and treatment of invasive candidiasis in the intensive care setting. Eur J Microbiol Infect Dis 2004; 23: 739-44.
9. Cotterill S. Antimicrobial prescribing in patients on hemofiltration. J Antimicrob Chemother 1995; 36: 773-80.
10. Golper TA, Marx MA. Drug adjustments during continuous renal replacement therapies. Kidney Int 1998; 53 Suppl 66: 165-8.
11. Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006; 45: 649-63.
12. Muhl E, Martens T, Iven H et al. Influence of continuous veno-venous haemodiafiltration and continuous veno-venous haemofiltration on the pharmacokinetics of fluconazole. Eur J Clin Pharmacol 2000; 56: 671-8.
13. Saari TI, Laine K, Leino K et al. Effect of voriconazole on the Pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clin Pharmacol Ther 2006; 79: 362-70.
14. Fuhrmann V, Schenk P, Jaeger W et al. Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous hemodiafiltration. J Antimicrob Chemother 2004; 54: 780-4.
15. Pennick GJ, Clark M, Sutton DA et al. Development and validation of a high-performance liquid chromatography assay for voriconazole. Antimicrob Agents Chemother 2003; 47: 2348-50.
16. Pfizer Global Research and Development. Briefing Document for Voriconazole, for the FDA Antiviral Drug Products Advisory Committee, 1-56, 2001. http://www.fda.gov/ohrms/dockets/ac/01/briefing/ 3792b2_01_Pfizer.pdf (3 September 2006, date last accessed).
17. Purkins L, Wood N, Ghahramani K et al. Pharmacokinetics and safety of voriconazole following intravenous to oral dose escalation regimens. Antimicrob Agents Chemother 2002; 46: 2546-53.
18. Robatel C, Rusca M, Padoin C et al. Disposition of voriconazole during continuous veno-venous hemodiafiltration (CVVHDF) in a single patient. J Antimicrob Chemother 2004; 54: 269-70.
19. Purkins L, Wood N, Greenhalgh K et al. The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum anti-fungal agent. Br J Clin Pharmacol 2003; 56: 2-9.
20. Mohammedi I, Piens MA, Padoin C et al. Plasma levels of vori-conazole administered via a nasogastric tube to critically ill patients. Eur J Clin Microbiol Infect Dis 2005; 24: 358-60.
21. Peng LW, Lien Y-H. Pharmacokinetics of single, oral-dose vori-conazole in peritoneal dialysis patients. Am J Kidney Dis 2005; 45: 162-6.
22. Tamion F, Hamelin K, Duflo A et al. Gastric emptying in mechanically ventilated critically ill patients: Effect of neuromuscular blocking agent. Intensive Care Med 2003; 29: 1717-22.
23. Tribl B, Sibbald J, Vogelsang H et al. Exocrine pancreatic dysfunction in sepsis. Eur J Clin Invest 2003; 33: 239-43.
24. Kang JY. The gastrointestinal tract in uremia. Dig Dis Sci 1993; 38: 257-68.
25. Magnusson M, Magnusson K-E, Sundqvist T et al. Impaired intestinal barrier function measured by differently sized polyethylene glycols in patients with chronic renal failure. Gut 1991; 32: 754-9.
26. Vaziri ND, Dure-Smith B, Miller R et al. Pathology of gastrointestinal tract in hemodialysis patients: An autopsy study of 78-patients. Am. J Gastroenterol 1985; 80: 608-11.
27. von Mach MA, Burhenne J, Weileman LS. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. BMC Clin Pharmacol 2006; 6: 6-11.
28. Tomaszewski K, Purkins L. The pharmacokinetics (PK) and safety of sulphobutylether-β-cyclodextrin (SBECD). In: Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2001. Abstract A-23, p. 3. American Society for Microbiology, Washington, DC, USA.
29. Mohr JF, Finkel KW, Rex AH et al. Pharmacokinetics of intravenous itraconazole in stable hemodialysis patients. Antimicrob Agents Chemother 2004; 48: 3151-3.
30. Fish DN, Teitelbaum I, Abraham E. Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 2005; 49: 2421-8.
31. Valtonen M, Tiula E, Takkunen O et al. Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother 2001; 48: 881-5.
32. Wallis SC, Mullany DV, Lipman J et al. Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous haemodiafiltration. Intensive Care Med 2001; 27: 665-72.
33. Banyai M, Thalhammer F, El-Menyawi I et al. Pharmacokinetics of cefpirome during continuous venovenous hemofiltration: Rationale for an 8-hour dosing interval. Clin Pharmacol Ther 2000; 67: 368-72.